肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2014年
9期
626-628
,共3页
商健彪%邓丽霞%高文英%丁可%谈燕飞%黄秀春%余伟冰%刘方颖%李叶枚
商健彪%鄧麗霞%高文英%丁可%談燕飛%黃秀春%餘偉冰%劉方穎%李葉枚
상건표%산려하%고문영%정가%담연비%황수춘%여위빙%류방영%리협매
粒细胞巨噬细胞集落刺激因子,重组%鼻咽肿瘤%放射性口腔黏膜炎
粒細胞巨噬細胞集落刺激因子,重組%鼻嚥腫瘤%放射性口腔黏膜炎
립세포거서세포집락자격인자,중조%비인종류%방사성구강점막염
Granulocyte macrophage colony-stimulating factors,recombinant%Nasopharyngeal neoplasms%Radiation oral mucositis
目的 观察重组人粒细胞巨噬细胞集落刺激因子(rhGM-CSF)早期干预对鼻咽癌患者放射性口腔黏膜炎的疗效.方法 将75例鼻咽癌患者按随机数字表法分为预防组、治疗组、对照组各25例,预防组为放疗第一天开始使用rhGM-CSF漱口,治疗组和对照组为放疗至出现口腔黏膜炎开始分别使用rhGM-CSF漱口及对照药物(0.9％氯化钠溶液500 ml+维生素B1240 mg+丁卡因100 mg)漱口.采用通用毒性标准(CTC)评价和记录口腔黏膜炎发生时间及损伤程度.结果 预防组口腔黏膜炎发生时间较治疗组和对照组延迟,差异具有统计学意义[预防组、治疗组及对照组分别为(15.2±3.2)、(12.1±2.7)、(12.0±2.6)d;t=3.725,P=0.001;t=3.939,P=0.000],口腔黏膜损伤程度方面,预防组较对照组、治疗组减轻,预防组Ⅱ级及以上口腔黏膜炎发生率为68％(17/25),治疗组为92％(23/25),对照组为100％(25/25)(P=0.000).亚组分析结果显示,预防用药能更好降低Ⅱ级及以上口腔黏膜炎发生率(P＜0.05),治疗用药能更好地降低Ⅱ级及以上口腔黏膜炎发生率(P＜0.05).结论 rhGM-CSF早期干预能更好地改善鼻咽癌患者放射性口腔黏膜炎.
目的 觀察重組人粒細胞巨噬細胞集落刺激因子(rhGM-CSF)早期榦預對鼻嚥癌患者放射性口腔黏膜炎的療效.方法 將75例鼻嚥癌患者按隨機數字錶法分為預防組、治療組、對照組各25例,預防組為放療第一天開始使用rhGM-CSF漱口,治療組和對照組為放療至齣現口腔黏膜炎開始分彆使用rhGM-CSF漱口及對照藥物(0.9％氯化鈉溶液500 ml+維生素B1240 mg+丁卡因100 mg)漱口.採用通用毒性標準(CTC)評價和記錄口腔黏膜炎髮生時間及損傷程度.結果 預防組口腔黏膜炎髮生時間較治療組和對照組延遲,差異具有統計學意義[預防組、治療組及對照組分彆為(15.2±3.2)、(12.1±2.7)、(12.0±2.6)d;t=3.725,P=0.001;t=3.939,P=0.000],口腔黏膜損傷程度方麵,預防組較對照組、治療組減輕,預防組Ⅱ級及以上口腔黏膜炎髮生率為68％(17/25),治療組為92％(23/25),對照組為100％(25/25)(P=0.000).亞組分析結果顯示,預防用藥能更好降低Ⅱ級及以上口腔黏膜炎髮生率(P＜0.05),治療用藥能更好地降低Ⅱ級及以上口腔黏膜炎髮生率(P＜0.05).結論 rhGM-CSF早期榦預能更好地改善鼻嚥癌患者放射性口腔黏膜炎.
목적 관찰중조인립세포거서세포집락자격인자(rhGM-CSF)조기간예대비인암환자방사성구강점막염적료효.방법 장75례비인암환자안수궤수자표법분위예방조、치료조、대조조각25례,예방조위방료제일천개시사용rhGM-CSF수구,치료조화대조조위방료지출현구강점막염개시분별사용rhGM-CSF수구급대조약물(0.9％록화납용액500 ml+유생소B1240 mg+정잡인100 mg)수구.채용통용독성표준(CTC)평개화기록구강점막염발생시간급손상정도.결과 예방조구강점막염발생시간교치료조화대조조연지,차이구유통계학의의[예방조、치료조급대조조분별위(15.2±3.2)、(12.1±2.7)、(12.0±2.6)d;t=3.725,P=0.001;t=3.939,P=0.000],구강점막손상정도방면,예방조교대조조、치료조감경,예방조Ⅱ급급이상구강점막염발생솔위68％(17/25),치료조위92％(23/25),대조조위100％(25/25)(P=0.000).아조분석결과현시,예방용약능경호강저Ⅱ급급이상구강점막염발생솔(P＜0.05),치료용약능경호지강저Ⅱ급급이상구강점막염발생솔(P＜0.05).결론 rhGM-CSF조기간예능경호지개선비인암환자방사성구강점막염.
Objective To evaluate the early intervention efforts of recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF) against nasopharyngeal cancer with radiation-induced oral mucositis.Methods A total of 75 patients with nasopharyngeal cancer were randomly assigned to 3 groups:the prevention group (n =25) used rhGM-CSF when radiation started one day,the treatment group (n =25) and the control group (n =25) used rhGM-CSF when oral mucositis occurred.Criteria of CTC was used to evaluate the duration of oral mucositis and degree of oral pain.Results The prevention group had a longer duration of oral mucositis of oral mucositis when comparing with the treatment group and the control group (15.2±3.2),(12.1±2.7),(12.0±2.6) d (t =3.725,P =0.001; t =3.939,P =0.000).As compared with the control and experiment group,the degree of mucosal damage in the prevention group was significantly lower.Ⅱ level and above oral mucositis were about 68 ％ (17/25),92 ％ (23/25) and 100 ％ (25/25) respectively (P =0.000).According to subgroup analysis,prophylactic rhGM-CSF in radiation-induced oral mucositis can better reduce the incidence of Ⅱ level and above oral mucositis (P ＜ 0.05),and treatment group can reduce the incidence of Ⅲ level oral mucositis (P ＜ 0.05).Conclusion rhGM-CSF early intervention can better improve nasopharyngeal cancer with radiation-induced oral mucositis.
